Raphael Mechoulam, « père de la recherche sur le cannabis », est décédé à l’âge de 92 ans Aurélien BERNARD Newsweed.org, 10 mars 2023 Le célèbre scientifique spécialiste du cannabis Raphael Mechoulam est décédé à l’âge de 92 ans. La nouvelle a été annoncée par des amis et des collègues qui ont fait part de leurs condoléances et de leurs hommages. « C’est un jour très triste pour moi, pour la communauté scientifique et pour la communauté du cannabis. Le professeur Raphael Mechoulam, que nous appelions Raphi, était l’un des plus grands scientifiques que j’aie jamais rencontrés, mon professeur et mon mentor à bien des égards. Je crois [...]
Lire la suiteThe Cannabis sativa Versus Cannabis indica Debate : An Interview with Ethan Russo, MD Daniele Piomelli and Ethan B. Russo Cannabis and Cannabinoid Research, 2016, Volume 1.1, 44-46. Doi : 10.1089/can.2015.29003.ebr Dr. Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Medical Director of PHYTECS, a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system. Previously, from 2003 to 2014, he served as Senior Medical Advisor and study physician to GW Pharmaceuticals for three Phase III clinical trials of Sativex for alleviation of cancer pain unresponsive to optimized opioid treatment and studies of Epidiolex for intractable epilepsy. He has held [...]
Lire la suiteThe Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances : Origins Samuel D. Banister and Mark Connor Handbook of Experimental Pharmacology, # Springer International Publishing AG, part of Springer Nature 2018 doi : 10.1007/164_2018_143 Contents 1 Introduction 2 Chemical Classification of Synthetic Cannabinoid Receptor Agonists 3 Cannabinoid Type 1 Receptor (CB1) Structure and Function 4 Historical Synthetic Cannabinoid Receptor Agonists 4.1 Classical Cannabinoids and Phytocannabinoid Analogs 4.2 Nonclassical Cannabinoids 4.3 Aminoalkylindoles (AAIs) 5 Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances 5.1 Molecular Hybridization 5.2 Bioisosteric Fluorination 6 Conclusions References Abstract Synthetic cannabinoid receptor agonists (SCRAs) have proliferated as new psychoactive substances (NPS) over the past decade. Relative to other classes of NPS, SCRAs [...]
Lire la suiteCannabis and synaptic reprogramming of the developing brain Anissa Bara, Jacqueline- Marie N. Ferland, Gregory Rompala, Henrietta Szutorisz and Yasmin L. Hurd Nature Reviews | Neuroscience, 2021, https://doi.org/10.1038/s41583-021-00465-5 Abstract Recent years have been transformational in regard to the perception of the health risks and benefits of cannabis with increased acceptance of use. This has unintended neurodevelopmental implications given the increased use of cannabis and the potent levels of Δ9-tetrahydrocannabinol today being consumed by pregnant women, young mothers and teens. In this Review, we provide an overview of the neurobiological effects of cannabinoid exposure during prenatal/perinatal and adolescent periods, in which the endogenous cannabinoid system plays [...]
Lire la suiteEarly phytocannabinoid chemistry to endocannabinoids and beyond Raphael Mechoulam, Lumír O. Hanuš, Roger Pertwee and Allyn C. Howlett NATURE REVIEWS | NEUROSCIENCE, 2014, 15, 757-764. Doi : 10.1038/nrm3811 Abstract Isolation and structure elucidation of most of the major cannabinoid constituents — including Δ9-tetrahydrocannabinol (Δ9-THC), which is the principal psychoactive molecule in Cannabis sativa — was achieved in the 1960s and 1970s. It was followed by the identification of two cannabinoid receptors in the 1980s and the early 1990s and by the identification of the endocannabinoids shortly thereafter. There have since been considerable advances in our understanding of the endocannabinoid system and its function in the [...]
Lire la suitePotential combinations of endocannabinoid/endocannabinoid-like compounds and antibiotics against methicillin-resistant Staphylococcus aureus Mark Feldman, Reem Smoum, Raphael Mechoulam, Doron Steinberg PLoS One, April 15, 2020, 1-13. Doi : 10.1371/journal.pone.0231583 Abstract Infections caused by antibiotic-resistant strains of Staphylococcus aureus have reached epidemic proportions globally. Our previous study showed antimicrobial effects of anandamide (AEA) and arachidonoyl serine (AraS) against methicillin (MET)-resistant S. aureus (MRSA) strains, proposing the therapeutic potential of these endocannabinoid/endocannabinoid-like (EC/EC-like) agents for the treatment of MRSA. Here, we investigated the potential synergism of combinations of AEA and AraS with different types of antibiotics against MRSA grown under planktonic growth or biofilm formation. The most effective [...]
Lire la suiteHigh Times for Painful Blues : The Endocannabinoid System in Pain-Depression Comorbidity Marie Fitzgibbon, David P. Finn, Michelle Roche International Journal of Neuropsychopharmacology, 2016, 19, (3), 1–20 doi : 10.1093/ijnp/pyv095 Abstract Depression and pain are two of the most debilitating disorders worldwide and have an estimate co-occurrence of up to 80%. Comorbidity of these disorders is more difficult to treat, associated with significant disability and impaired healthrelated quality of life than either condition alone, resulting in enormous social and economic cost. Several neural substrates have been identified as potential mediators in the association between depression and pain, including neuroanatomical reorganization, monoamine and neurotrophin depletion, dysregulation [...]
Lire la suiteBIBLIOGRAPHIE : Système endocannabinoïdes et récepteurs aux cannabinoïdes Dr Christian Sueur, GRECC, avril 2020. 1 - Système endocannabinoïde : 1 - 7 2 - Récepteurs des cannabinoïdes : 8 - 13 3 - THC et récepteurs non-cannabinoïdes : 14 4 - CBD et récepteurs non cannabinoïdes : 15 5 - Neurophysiologie des endocannabinoïdes : 16 - 19 6 - Neuropharmacologie des cannabinoïdes de synthèse : 20 - 21 7 - Neuropharmacologie des Phytocannabinoïdes : 22 - 29
Lire la suitePlant cannabinoids : a neglected pharmacological treasure trove Raphael Mechoulam British Journal of Pharmacology, 2005, 146, 913–915 doi : 10.1038/sj.bjp.0706415 Most of the cannabinoids in Cannabis sativa L. have not been fully evaluated for their pharmacological activity. A publication in this issue presents evidence that a plant cannabinoid, D9-tetrahydro-cannabivarin is a potent antagonist of anandamide, a major endogenous cannabinoid. It seems possible that many of the non-psychoactive constituents of this plant will be of biological interest. Keywords : Anandamide; CB1 receptor antagonist; CB2 receptor antagonist; mouse vas deferens; D9 tetrahydrocannabinol; D9-tetrahydrocannabivarin; -(þ)-(R)- WIN55212 Cannabis sativa L. produces more than 60 terpeno-phenols that have not been detected [...]
Lire la suiteCannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal Francisco Navarrete, Auxiliadora Aracil-Fernández and Jorge Manzanares British Journal of Pharmacology, 2018. Doi : 10.1111/bph.14226 BACKGROUND AND PURPOSE Cannabidiol (CBD) represents a promising therapeutic tool for treating cannabis use disorder (CUD). This study aimed to evaluate the effects of CBD on the behavioural and gene expression alterations induced by spontaneous cannabinoid withdrawal. EXPERIMENTAL APPROACH Spontaneous cannabinoid withdrawal was evaluated 12 h after cessation of CP-55,940 treatment (0.5 mg·kg1 every 12 h, i.p.; 7 days) in C57BL/6J mice. The effects of CBD (5, 10 and 20 mg·kg1, i.p.) on withdrawal-related behavioural signs were evaluated by [...]
Lire la suite